We focus on endogenous molecules. Our Nitric Oxide donating platform allows to modify endogenous molecules such as prostaglandins. Finally, it gives multi-target endogenous drug candidates with advanced therapeutic efficacy. Being endogenous, our molecules have nearly zero toxicity.
Gurus’ Nitric Oxide donating platform allows to modify endogenous molecules such as prostaglandins. Finally, it gives multi-target ( not single-target) endogenous drug candidates with advanced therapeutic efficacy.
Advantage # 1: action to all key biotargets
Gurus’ drug candidates act on all key biotargets involved in the pathology. The disease influence on several biotargets in human’s organism. So, the effective drug must act the same way.
Advantage # 2: synchronous action
Our molecules act synchronously on all key biotargets that provides very powerful impact. Several traditional drugs can cover several biotargets also, but they can’t act synchronously on them. To act synchronously one molecule is needed, not several.
Advantage # 3: safe for organism
Being endogenous, our molecules have nearly zero toxicity.
Advantage # 4: crucial modification of existing drugs
The Platform can be used to modify existing drug substances or API, that crucially improves their efficacy and diminish the toxicity. So, the platform can generate new best-in-class molecule with new IP (patents) from existing drugs.
Molecules generated by platform
Critical Limb Ischemia treatment
Market value of the Platform in 2025: $15-30B
Investor’s Value Growth: x20+